FDA Approves ETICOVO™ (etanercept-ykro), Samsung Bioepis' Second Anti-TNF Medicine in the United States - BioSpace

FDA Approves ETICOVO™ (etanercept-ykro), Samsung Bioepis' Second Anti-TNF Medicine in the United States  BioSpace

Samsung Bioepis expands autoimmune portfolio in the United States with FDA approval of ETICOVO™ (etanercept-ykro), a biosimilar referencing ENBREL®i ...



Comments

Post a Comment

Popular posts from this blog